11 › 11.1
11.1 Multidisciplinary management
Pages 69–71 · open in PDF
Recommendations in this section
- Class ILevel B1A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and death.
- Class ILevel AHF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death.
- Class ILevel B2Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 69 · PDF
10.9. Other non-cardiovascular comorbidities Infections may cause WHF and can precipitate HFH.925,926 Infections should ideally be prevented or, if present, promptly recognized and treated to avoid disease progression.927–930 Influenza vaccination is associated with a reduced risk of pneumonia and all-cause death in patients with HF.931–936 Thus, influenza and pneumococcal vaccination should be considered in all patients with HF in order to reduce the risk of infection-related complications.935 Thyroid dysfunction can cause changes in cardiac function and structure and may precipitate DHF.937,938 Assessment of thyroid function is recommended in patients with de novo HF or DHF and should be regularly assessed during follow-up of patients with HF. Treatment of thyroid dysfunction should be guided by endocrine guidelines.939–942 Hyperuricaemia and consequent gout attacks can be frequent in patients with HF, mainly caused or precipitated by diuretic treatment.943,944 Allopurinol is recommended as the first choice to chronically reduce uric acid levels in patients with HF,945 whereas colchicine can be used for acute gout attacks. Non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors are not recommended in patients with HF because they may precipitate decompensation and worsen kidney function.942,946–948 Heart failure and erectile dysfunction frequently coexist.949,950 Cardioselective beta-blockers should be preferred in patients with HF and erectile dysfunction, mainly bisoprolol and nebivolol, started at the lowest doses.897 In the presence of erectile dysfunction symptoms, phosphodiesterase-V inhibitors are generally safe and can be considered in patients who are compensated,951 avoiding their concomitant use with nitrates.952 Recommendation Table 22 — Recommendations for other non-cardiovascular comorbidities (see Evidence Tables 92 and 93)
Influenza and pneumococcal vaccination should be considered in patients with HF to reduce the risk of pneumonia complications,
Recommendation Table 23 — Recommendations for the multidisciplinary management of heart failure (see Evidence Tables 94–96)
hospitalization, and death.
NSAIDs and COX-2 inhibitors are not recommended in patients with HF as they increase the risk of HF worsening and
HFH.942,946–948 COX-2, cyclooxygenase-2; HF, heart failure; HFH, heart failure hospitalization; NSAID, non-steroidal anti-inflammatory drug. a Class of recommendation. b Level of evidence.
11. Multidisciplinary team management, long-term follow-up, and patient care 11.1. Multidisciplinary management of heart failure Multidisciplinary care for HF combines the expertise of various professionals to provide integrated, patient-centred care that
Recommendations A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and
death.964–967 HF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death.977 Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death.978–981 HF, heart failure; HFH, heart failure hospitalization. a Class of recommendation. b Level of evidence.
improves both clinical outcomes and QoL for patients (Figure 21). Access to healthcare professionals with awareness of HF and expertise in its diagnosis and management is essential for early detection and better outcomes. Multidisciplinary HF care involves generalist and specialist healthcare professionals,955 including cardiologists, cardiothoracic surgeons, specialist nurses, pharmacists, and physiologists (Figure 21) (see Supplementary data online, Section S8.1).17,956–963 Management by an HF multidisciplinary team (HF-MDT) across outpatient and inpatient settings improves outcomes for people with HF.962,964–967 The literature evaluates various methods of delivering HF management programmes enabling local HF services to design services tailored to their HF-MDT and the structure of their healthcare system. A meta-analysis of 16 RCTs with 3999 eligible patients evaluating the benefits of multidisciplinary HF clinics compared with usual care demonstrated a reduction in HFH.967 A meta-analysis of eight RCTs with 1764 patients indicated that multidisciplinary teams may have the potential to reduce death, although a definitive RCT is needed.964 The benefits were more evident in patients with a recent emergency department presentation or HFH.966 Other methods of delivery, including home visits and transitional care models, are given in Supplementary data online, Section S8.1.145,962,965,968–972 Healthcare professionals involved in the management of HF, whether specialist or generalist, should be equipped with the knowledge required to effectively assess and manage HF through appropriate education and training.958,973,974 Malnutrition has been associated with worse prognosis in patients with HF.738 Thus, nutritional assessment and dietary interventions can be useful.588,589 No evidence supports fluid restriction in chronic HF.975,976
Page 70 · PDF
Figure 21 Core members of the heart failure team with expanded team members depending on patient needs and local availability. AP, allied professional; EP, electrophysiology; HF, heart failure.
Page 71 · PDF
11.4. Exercise training and cardiac rehabilitation
Education, self-care, and lifestyle advice empower patients and their caregivers in managing HF and engage in shared decisionmaking. Self-care incorporates education and strategies to support maintenance, monitoring, and management of HF.973 The aim is to ensure people with HF and their caregivers are equipped with knowledge and skills and be partners in their care and not simply recipients of information and treatments. The benefits of self-care are described in a meta-analysis of 20 RCTs including 5624 patients.977 Self-management interventions on the background of usual HF care improved QoL and reduced time to HFH or all-cause death. There may be some barriers to self-care, but these can be overcome by careful design of programmes982,983 (see Supplementary data online, Section S8.2). Effective self-care enhances QoL, reduces symptom severity, and lowers the risk of hospitalization. It is essential that HF professionals collaborate with patients and caregivers, using shared decision-making to develop personalized self-care plans (Supplementary data online, Table S24).
11.4.1. Benefits of exercise training according to heart failure stage and phenotype
11.3. Implementation and adherence to therapy 11.3.1. Implementation and optimization Implementation of HF therapies should be individualized, based on available evidence, and involve the HF-MDT and patients and caregivers. Yet, there remain delays to implementation and optimization of treatments.984–986 Multivariable adjusted large observational studies suggest that among the strongest factors associated with improved FMT, AMT, and GDIT use is access to cardiologist specialists.987–990 For barriers and facilitators to improved implementation of HF therapies, including clinical inertia, impact of race, ethnicity, gender, and health literacy, see Supplementary data online, Table S25. Evidence supports the role of HF nurses and pharmacists in the implementation and optimization of HF therapies and avoidance of unnecessary side effects of polypharmacy.991–994 Pharmacists play a key role in ensuring safe and effective use of medicines, including medication reconciliation and the optimization of therapies for comorbidities. Development of the HF-MDT to support the implementation and optimization of HF and to address the barriers that exist is key to improving outcomes for patients.
11.3.2. Long-term adherence Adherence to self-care strategies and therapies is essential to control symptoms, limit disease progression, and reduce hospitalization and death.981 Factors that impact adherence and affect clinical outcomes include health literacy, polypharmacy, and managing multiple health conditions.978,979,995 Strategies to improve adherence in the context of HF have been described elsewhere and provide guidance on the use of education tailored to the individual, communication skills, polypharmacy review, and co-ordinated care.980,996 Central to these is the importance of the HF-MDT recognizing the barriers to adherence, assessing those barriers, and utilizing other members of the health and social care team to address them.
There is consistent evidence that exercise training improves exercise tolerance and health-related QoL in patients with HF.94 HF-ACTION was the largest RCT on exercise training in HF including 2331 patients with LVEF ≤35% (NYHA classes II–IV). Compared with usual care, supervised exercise training plus usual care showed modest, non-significant reductions in allcause death and hospitalizations. However, prespecified adjustments revealed significant reductions in CV death and HFH.997 A systematic review of 60 trials with 8728 patients (mean age 63 years, mean LVEF 32%) confirmed improvements in functional capacity, QoL, and reductions in HFH with exercise training but found no reduction in death.998 Similar findings were reported by another systematic review focusing on HFrEF (LVEF <40%).94,999 In HFpEF, exercise training is safe and significantly enhances exercise capacity and QoL, with no significant impact on diastolic function, arterial stiffness, or vascular function, and insufficient data exist to assess its impact on clinical events, such as death and hospital admissions, due to small sample sizes and short follow-up times.1000,1001 Most trials in HF, except for HF-ACTION, are too small to reliably evaluate the effects of exercise rehabilitation across subgroups (see Supplementary data online, Section S8.4).1002,1003 In patients with long-term mechanical support, the benefit of exercise training on functional capacity has been demonstrated.1004,1005 The Rehab-VAD trial showed that moderate intensity aerobic training was safe in patients with continuousflow LVADs and yielded significantly improved health status, treadmill time, and leg strength, without significant improvements in peak oxygen consumption.1006 If a patient with advanced HF can tolerate physical activity, exercise training can improve QoL.1007 Exercise training before and after heart transplantation should follow recommendations according to the consensus document.1008
11.4.2. Safety and contraindications No major adverse effects of exercise training were reported in the included studies of above systematic reviews and meta-analyses.1001,1009 However, exercise interventions should only be initiated in stable individuals after initiation of FMT. Exercise training is contraindicated in patients with refractory/unstable angina and other high-risk CV conditions (e.g. high-grade arrhythmias, DHF, active thromboembolic disease) and in any other unstable non-cardiac condition (e.g. active infection, uncontrolled diabetes, end-stage cancer, COPD exacerbation).94
11.4.3. Exercise prescription A personalized training programme, with the mode of delivery, type, and intensity tailored to the patient’s preferences, risk level, and comorbidities, is recommended to improve uptake of exercise-based cardiac rehabilitation. Exercise training should be started as part of cardiac rehabilitation and be individually prescribed according to the FITT model (frequency, intensity,
11.2. Patient education, self-care, and lifestyle advice